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Abstract
ABO incompatibility is commonly observed in stem cell transplantation and its impact in this set-
ting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often
used as an alternative stem cell source but are associated with increased transplant related compli-
cations. Whether ABO incompatibility affects outcome in MMURD transplantation for acute
myeloid leukemia (AML) patients is unknown. We evaluated 1,013 AML patients who underwent
MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between
ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval
(CI), 28–39; for ABO matched vs. 36%; 95% CI, 32–40; for ABO mismatched; P5 .32], and nonre-
lapse mortality (28%; 95% CI, 23–33; for ABO matched vs. 25%; 95% CI, 21–29; for ABO
mismatched; P5 .2). Three year survival was 40% for ABO matched and 43% for ABO mis-
matched patients (P5 .35), Leukemia free survival rates were also comparable between groups
(37%; 95% CI, 32–43; for ABO matched vs. 38%; 95% CI, 33–42; for ABO mismatched; P5 .87).
Incidence of grade II-IV acute graft versus host disease was marginally lower in patients with major
ABO mismatching (Hazard ratio of 0.7, 95% CI, 0.5–1; P5 .049]. ABO incompatibility probably has
no significant clinical implications in MMURD transplantation.
1 | INTRODUCTION
For acute myeloid leukemia (AML) patients lacking a matched sibling
donor or a fully HLA matched unrelated donor, alternative stem cell
donor sources must be sought to proceed with allogeneic hematopoietic
cell transplantation. At present, these include transplantation from an
haploidentical related donor, using an umbilical cord blood stem cell prod-
uct or using a partially HLA-mismatched unrelated donor (MMURD).1
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While MMURD transplantation presents an attractive and readily avail-
able option for some patients, widespread use has been limited to some
degree by an increased risk for graft failure,2–4 higher rates of GVHD,5,6
and an increased risk of nonrelapse mortality (NRM),7 all of which may
lead to compromised survival. Thus, improving on transplant related out-
comes in MMURD is a major priority in the field of alternative donor
transplantation. ABO incompatibility involves antibody production against
donor red blood cells (major ABO incompatibility) or against the recipi-
ent’s red blood cells (minor ABO incompatibility) and is seen in 25–50%
of allogeneic stem cell transplantations.8,9 Yet, it remains unclear whether
ABO incompatibility is of actual clinical significance for transplanted
patients. A multitude of published reports in a wide range of hematologic
malignancies, conditioning regimens, and donor sources have yielded
conflicting data with regard to the actual impact of ABO mismatching on
patient outcome.9–16 Previous publications in AML patients undergoing
MMURD did not address the potential clinical significance of ABO mis-
matching on clinical and transplanted related outcomes. In this analysis of
the acute leukemia working party (ALWP) of the European Society for
Blood and Marrow Transplantation (EBMT) we set out to investigate the
clinical effects of ABO incompatibility in a large group of adult AML
patients undergoing MMURD transplantation.
2 | METHODS
2.1 | Study design and data collection
This multicenter retrospective analysis was approved by the ALWP, in
accordance with the EBMT guidelines for retrospective studies. The
EBMT is a voluntary working group of more than 500 transplant depart-
ments that are required to report all consecutive stem cell transplanta-
tions and follow-ups on a yearly basis. Audits are routinely performed to
determine the accuracy of the data. The study protocol was approved
by the institutional review board at each site and complied with
country-specific regulatory requirements. The study was conducted in
accordance with the Declaration of Helsinki and Good Clinical Practice
guidelines. All patients provided written informed consent authorizing
the use of their personal information for research purposes. The list of
institutions reporting data included in this study is provided in the
Supporting Information data.
For the purpose of this analysis, eligible patients were adults over
the age of 18 with AML who were transplanted from an HLA mis-
matched donor at one or two loci (8/10; 9/10) (-A, -B, -C, DRB1, -DQB1).
Patients who had undergone previous allogeneic stem cell transplantation
were excluded from the analysis. Major ABO incompatibility was defined
as serological evidence for recipient derived antibodies directed against
donor red cells, minor ABO incompatibility was defined as serological evi-
dence for donor derived antibodies directed against the recipient’s red
cells, while bi-directional incompatibility comprised serological evidence
of both donor and recipient derived red cell directed antibodies. Regi-
mens were classified as myeloablative conditioning (MAC) or reduced
intensity conditioning (RIC) based on published criteria.17
2.2 | Statistical analysis
The primary end point of the study was overall (OS) and leukemia-free
survival (LFS). Secondary endpoints included disease relapse incidence
(RI), NRM, engraftment, incidences, GVHD-free/relapse-free survival
(GRFS), defined as events including grade 3–4 acute GVHD, systemic
therapy-requiring chronic GVHD, relapse, or death in the first post-
HCT year, and severity of acute and chronic GVHD. NRM was defined
as death without previous relapse. RI was defined on the basis of mor-
phological evidence of leukemia in bone marrow or other extramedul-
lary organs. LFS was defined as the time from transplantation to first
event (either relapse or death in complete remission. Engraftment was
defined as sustained achievement of an absolute neutrophil count of
over 0.5 3 109/l. Grading of acute and chronic GVHD was performed
using established criteria.18 Chronic GVHD was classified as limited or
extensive according to usual criteria.19 GRFS after HSCT was defined
as survival in the absence of grade 3–4 acute GVHD, extensive chronic
GVHD and relapse. Cumulative incidence curves were used for RI and
NRM in a competing risks setting, since death and relapse are compet-
ing. Competing events considered for acute and chronic GVHD were
relapse and death. Probabilities of OS and LFS were calculated using
the Kaplan–Meier estimate. All tests were two-sided with the type I
error rate fixed at 0.05. Statistical analyses were performed with SPSS
22 (SPSS, Chicago, IL), and R 3.2.3 (R Development Core Team, Vienna,
Austria) software packages.
3 | RESULTS
3.1 | Patient demographics
A total of 1,013 AML patients who underwent HLA mismatched allo-
geneic stem cell transplantation between 2005 and 2014 was identi-
fied and analyzed. As most of the patients were transplanted with
peripheral blood mobilized grafts (n5876), we decided to initially focus
our analysis on this group of patients. As summarized in Table 1, the
median age of patients was comparable between the various ABO
matched and mismatched groups. Most patients were transplanted at
first complete remission (CR1) with RIC being the most commonly used
conditioning modality. The vast majority of patients in our cohort
(range, 88–91%) were mismatched at a single allele, namely 9/10.
Cyclosporine based regimens for GVHD prophylaxis were used for
most of the patients (889 of 1013; 87%) in the cohort while the rest
were given prophylaxis with various combinations consisting of myco-
phenolate mofetil, tacrolimus, sirolimus, and post-transplant cyclophos-
phamide. As outlined in Supporting Information Table S1, leukemia,
GVHD, and infection accounted for most deaths in the analyzed cohort
whereas ABO status had no clinical impact on cause of death both in
patients transplanted with PB grafts (P5 .94) and those receiving BM
derived grafts (P5 .84).
3.2 | Engraftment
ABO matched patients and the three groups of ABO mismatched
patients (major, minor, bidirectional) did not significantly differ with
regard to engraftment rates at 30 days post transplantation (96, 95, 98,
and 97%, respectively, P5 .32). Univariate analysis for engraftment
rates also confirmed the absence of a statistically significant difference
between ABO matched and mismatched patients (93 vs. 95%; P5 .96).
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ABO matched, minor mismatched, and major mismatched patients
engrafted after a median of 16 days compared to 15 days required for
patients with a bidirectional mismatch (P5 .9).
3.3 | Acute and chronic GVHD
To evaluate the impact of ABO incompatibility we initially performed a
univariate analysis, which as shown in Table 2, demonstrated that the
incidence of grade II–IV acute GVHD did not differ to a statistically sig-
nificant degree between ABO matched and mismatched patients (33
vs. 28%; P5 .09). Severe acute GVHD, defined as grade III–IV GVHD,
was also not seen more frequently among ABO mismatched patients
(15 vs. 11%; P5 .14).
Additionally, the rates of 3 year chronic GVHD (38 vs. 35%;
P5 .43) and extensive chronic GVHD (17 vs. 14%, P5 .26) were also
comparable between ABO compatible and incompatible patients.
Patients who underwent in-vivo T-cell depletion were less likely to
experience chronic GVHD (35 vs. 47%; P5 .049) and extensive chronic
GVHD (14 vs. 24%; P5 .003) compared with those who did not
undergo T-cell depletion.
Multivariate analysis (Table 3) also confirmed the absence of a
statistically significant association between ABO matching and chronic
GVHD, however grade II–IV acute GVHD was significantly lower in
patients with major ABO mismatching [Hazard ratio (HR) of 0.7, 95%
confidence interval (CI), 0.5–1; P5 .049].
3.4 | RI and NRM
In univariate analysis there was no difference in RI at 3 years between
ABO matched and mismatched patients (34%; 95% CI, 28–39; for ABO
matched vs. 36%; 95% CI, 32–40; for ABO mismatched; P5 .32). Nei-
ther conditioning intensity patients (33%; 95% CI, 28–38; for MAC vs.
37%; 95% CI, 32–41; for RIC; P5 .26) nor degree of HLA mismatching
patients (36%; 95% CI, 32–39; for 9/10 mismatch vs. 31%; 95% CI,
21–41; for 8/10 mismatch; P5 .29) were found to affect RI in a statis-
tically significant manner. Multivariate analysis (Table 3) also did not
establish ABO compatibility to affect RI.
TABLE 1 Patient characteristics-peripheral blood grafts
Minor ABO mismatch Major ABO mismatch Bidirectional ABO mismatch
Variable ABO matched n5349 n5241 n5215 n571 Pa
Follow up duration in m, median (range) 24 (1.84–113.85) 34 (2.99–117.44) 32 (0.62–112.74) 41 (1.74–117.96)
Age in y, median (range) 52 (18–75.3) 54 (18.1–71.5) 52 (18.6–70.8) 50 (21.8–68.8) .266
Gender, n (%)
Male 193 (55.3) 134 (55.6) 120 (55.81) 33 (47.14) .6
Female 156 (44.7) 107 (44.4) 95 (44.19) 37 (52.86)
Performance status (Karnofsky)
KPS< 90% 98 (30) 64 (28.9) 50 (24.7) 13 (19.4) .234
KPS>590% 228 (69.9) 157 (71) 152 (75.2) 54 (80.6)
Disease status at transplant
CR1 190 (54.4) 127 (52.7) 113 (52.5) 41 (57.7) .11
CR2/3 89 (25.5) 62 (25.7) 64 (29.7) 9 (12.6)
Active disease 70 (20.06) 52 (21.5) 38 (17.6) 21 (29.5)
CMV D–/R– 88 (25.8) 68 (28.8) 50 (23.4) 17 (25.3) .92
CMV D1/R– 41 (12) 23 (9.7) 24 (11.2) 8 (11.9)
CMV D–/R1 105 (30.8) 70 (29.6) 61 (28.6) 18 (26.8)
CMV D1/R1 106 (31.1) 75 (31.7) 78 (36.6) 24 (35.8)
T-cell depletion ex-vivo
Yes 8 (2.2) 11 (4.5) 10 (4.6) 1 (1.4) .246
No 341 (97.7) 230 (95.4) 205 (95.3) 70 (98.5)
T-cell depletion in-vivo
Yes 301 (86.2) 204 (85) 190 (88.3) 60 (84.5) .725
No 48 (13.7) 36(15) 25 (11.6) 11 (15.4)
HLA matching
9/10 311 (89.1) 216 (89.6) 190 (88.3) 65 (91.5) .895
8/10 38 (10.8) 25 (10.3) 25 (11.6) 6 (8.4)
Female donor to male recipient 48 (13.7) 26 (10.8) 38 (17.7) 10 (14.4) .216
No female donor to male recipient 300 (86.2) 213 (89.1) 176 (82.2) 59 (85.5)
Conditioning regimen
Myeloablative 156 (44.7) 87 (36.1) 93 (43.2) 33 (46.4) .15
Reduced intensity 193 (55.3) 154 (63.9) 122 (56.7) 38 (53.5)
aP value of a test of the null hypothesis that all the groups are the same.
Abbreviations: CR1, first complete remission; CMV, cytomegalovirus.
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The NRM incidence at 3 years was also equivalent between the
ABO compatible and incompatible groups (28%; 95% CI, 23–33; for
ABO matched vs. 25%; 95% CI, 21–29; for ABO mismatched;
P5 .2). Of note, patients 9/10 HLA matched patients had signifi-
cantly decreased rates of NRM at 3 years compared to 8/10 HLA
matched patients (25%; 95% CI, 22–28; for 9/10 HLA matched
patients vs. 35%; 95% CI, 25–45; for 8/10 HLA mismatched
patients; P5 .02). Conditioning intensity did not significantly impact
on NRM (22%; 95% CI, 18–27; for MAC vs. 29%; 95% CI, 24–33;
for RIC; P5 .19). In the multivariate analysis presented in Table 3,
NRM incidence was not significantly different between ABO
matched and mismatched patients.
TABLE 3 Multivariable analysis of patient outcome following transplantation
Parameter
RI HR
(95% CI)
OS HR
(95% CI)
LFS HR
(95% CI)
NRM HR
(95% CI)
Acute GVHD grade
II–IV HR (95% CI)
Chronic GVHD
HR (95% CI)
Matched ABO (ref) 1 1 1 1 1 1
Minor ABO
mismatch
1.17
(0.86–1.61),
P5 .32
1.03
(0.8–1.33),
P5 .78
1.1
(0.87–1.4),
P5 .4
1.04
(0.73–1.48),
P5 .82
0.93
(0.66–1.31),
P5 .7
1.002
(0.71–1.4),
P5 .98
Major ABO
mismatch
1.11
(0.79–1.56),
P5 .53
1.02
(0.78–1.32),
P5 .87
1.01
(0.79–1.3),
P5 .9
0.92
(0.63–1.35),
P5 .69
0.71
(0.49–1.04),
P5 .08
0.94
(0.66–1.33),
P50.73
Bi–directional
ABO mismatch
1.004
(0.61–1.63),
P5 .98
0.73
(0.47–1.12),
P5 .16
0.83
(0.56–1.24),
P5 .37
0.63
(0.32–1.24),
P5 .18
0.84
(0.47–1.48),
P5 .55
0.9
(0.53–1.51),
P5 .69
Patient age
(10 year increment)
1.08
(0.96–1.21),
P5 .17
1.1
(1.006–1.21),
P5 .037
1.09
(1.003–1.19),
P5 .041
1.11
(0.97–1.27),
P5 .11
0.91
(0.8–1.04),
P5 .18
1.04
(0.92–1.18),
P5 .45
Donor age
(10 year increment)
0.96
(0.83–1.1),
P5 .57
1.04
(0.94–1.16),
P5 .39
1.03
(0.93–1.14),
P5 .53
1.12
(0.96–1.3),
P5 .12
0.93
(0.81–1.08),
P5 .38
0.93
(0.8–1.07),
P5 .34
Disease status at
transplant
CR1 (reference) 1 1 1 1 1 1
CR2 1.14
(0.81–1.62),
P5 .43
1.15
(0.88–1.51),
P5 .28
1.11
(0.86–1.43),
P5 .39
1.08
(0.74–1.57),
P5 .66
1.27
(0.88–1.82),
P5 .18
0.88
(0.63–1.23),
P5 .46
Active disease 2.34
(1.69–3.24),
P< .0001
2.04
(1.58–2.62),
P< .0001
2.11
(1.66–2.7),
P< .0001
1.85
(1.27–2.67),
P5 .001
1.28
(0.88–1.85),
P5 .18
1.06
(0.71–1.58),
P5 .74
CMV donor/
recipient matching
D–/R– (ref) 1 1 1 1 1 1
D1/R– 1.04
(0.65–1.66),
P5 .84
0.73
(0.49–1.09),
P5 .12
0.89
(0.61–1.29),
P5 .54
0.68
(0.36–1.29),
P5 .24
0.93
(0.56–1.54),
P5 .79
1.26
(0.79–2.02),
P5 .32
D–/R1 1.28
(0.91–1.8),
P5 .15
1.34
(1.03–1.76),
P5 .029
1.37
(1.06–1.77),
P5 .016
1.48
(1–2.2),
P5 .05
1.08
(0.75–1.56),
P5 .64
1.23
(0.85–1.79),
P5 .26
D1/R1 0.99
(0.69–1.41),
P5 .96
1.04
(0.78–1.37),
P5 .77
1.11
(0.85–1.45),
P5 .42
1.29
(0.86–1.94),
P5 .21
0.7
(0.47–1.04),
P5 .08
1.38
(0.95–1.99),
P5 .08
Female donor
to male recipient
vs. others
0.73
(0.49–1.1),
P5 .14
0.9
(0.66–1.22),
P5 .5
0.83
(0.62–1.12),
P5 .23
0.96
(0.63–1.47),
P5 .88
1.22
(0.83–1.8),
P5 .3
0.88
(0.6–1.3),
P5 .54
RIC vs. MAC
conditioning
1.005
(0.74–1.35),
P5 .97
1.02
(0.81–1.28),
P5 .86
1.01
(0.81–1.26),
P5 .87
1.03
(0.74–1.44),
P5 .84
1.01
(0.71–1.42),
P5 .95
0.82
(0.6–1.12),
P5 .22
KPS90% vs.
KPS<90%
0.8
(0.6–1.06),
P5 .13
0.68
(0.55–0.85),
P< .0001
0.74
(0.6–0.91),
P5 .005
0.67
(0.49–0.92),
P5 .014
1.01
(0.72–1.41),
P5 .94
1.03
(0.73–1.44),
P5 .85
Abbreviations: LFS, leukemia free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; RI, relapse incidence; NRM, non-relapse
mortality; GVHD, graft versus host disease; CR, complete remission; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; KPS,
Karnofsky performance status.
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3.5 | GRFS, LFS, and OS
As shown in Table 2, univariate analysis of GRFS, LFS, and OS at 3
years was comparable between ABO matched and mismatched
patients. Conversely, disease status at transplant and the conditioning
regimen significantly affected LFS with active disease correlating signif-
icantly with inferior LFS at 3 years (20%; 95% CI, 13–26; P< .0001)
while MAC was associated with a 3 year of 44% compared with 33%
with RIC (P5 .028). Similar correlations were also observed for OS and
GRFS (Table 2). In multivariate analysis, ABO compatibility status did
not significantly affect LFS and OS (Table 3) while increasing age, active
disease at transplant, and a decreased performance status were all pre-
dictive of inferior LFS and OS. Figure 1 depicts the various clinical
parameters stratified per ABO compatibility status
3.6 | Bone marrow graft cohort
To assess whether HLA mismatched patients transplanted with bone
marrow derived grafts were differentially affected by ABO mismatching
status we performed an additional separate analysis for this group of
patients. In all, a cohort of 137 patients was analyzed with their baseline
demographic data presented in Supporting Information Table S2. A uni-
variate analysis demonstrated that none of the clinical outcomes analyzed
(RI, NRM, LFS, OS, GRFS, acute GVHD, and chronic GVHD) were signifi-
cantly affected by ABO compatibility status (Supporting Information Fig-
ure S1). A subsequent multivariate analysis also did not confirm a
statistically significant difference between ABO matched and mismatched
patients with regard to the clinical outcome indices noted above.
3.7 | HLA mismatch focused analysis
As HLA-DQ mismatching has a minor impact on prognosis compared
with other HLA mismatches20 we wanted to assess whether exclusion
of this group of patients would influence the outcome of ABO mis-
matched patients. First, we confirmed that in our cohort there was no
statistically significant difference in the distribution of HLA-DQ mis-
matches between ABO matched and mismatched patients (P5 .15).
Next, we reanalyzed the data excluding the 156 patients who
were HLA-DQ mismatched. A univariate analysis showed that ABO
incompatible patients experienced decreased grade II–IV acute GVHD
rates compared to ABO matched patients (28 vs. 38%; P5 .011). A
subsequent multivariate analysis (Supporting Information Table S3)
confirmed that patients with major ABO mismatching experienced less
FIGURE 1 Impact of ABO incompatibility on clinical outcome indices in MMURD transplantation
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grade II–IV acute GVHD than ABO matched patients (HR of 0.57, 95%
CI, 0.37–0.88; P5 .01).
4 | DISCUSSION
ABO incompatibility is commonly seen in allogeneic hematopoietic cell
transplantations with a yet undecided consensus regarding the clinical
implications it holds on patient outcome. In this analysis, comparing the
outcomes of over a thousand adult AML patients who underwent
MMURD transplantations, we determine that in this specific clinical
setting, ABO mismatching does not affect prognosis in a clinical mean-
ingful way. Furthermore, we establish this lack of clinical significance to
be true both for peripheral blood mobilized grafts as well as for bone
marrow derived grafts.
Whereas the use of donors with one or two HLA mismatches
affords physicians the possibility of transplanting patients who would
otherwise may not have been able to benefit from a transplanted
based approach,4 this comes at a price of increased transplant related
morbidity and mortality. Multiple publications including those from the
Center for International Blood and Marrow Transplant Research
(CIBMTR)21 and the Japanese Society of Hematopoietic Cell Transplan-
tation22,23 as well as others6,24 have consistently demonstrated the
incremental detrimental consequences of increased HLA mismatching
regardless of graft source or conditioning intensity.4,25 Consequently,
attempts at optimizing transplant related factors are highly warranted.
Consistent with most major prior publications, we did not find ABO mis-
matching to correlate with inferior neutrophil engraftment. Whereas
neutrophils can express the ABO antigens which may theoretically lead
to slower engraftment following transplantation, several large registry
based analyses failed to show slower engraftment kinetics with ABO
mismatching,26–28 although Kimura and colleagues previously suggested
that major ABO incompatibility resulted in delayed engraftment of neu-
trophils, platelets, and red blood cells.9
Our data did indicate a potential mitigating role for major ABO mis-
matching on the incidence of grade II–IV acute GVHD. These data are in
agreement with those reported by Bacigalupu and colleagues29 showing
that patients with major ABO incompatibility experienced lower acute
GVHD rates compared with ABO matched and minor ABO mismatched
patients. More recently published data did not confirm the same effect
but did suggest a correlation between minor ABO incompatibility and
severe acute GVHD.30,31 While this observation currently lacks a clear
biological rationale, a possible explanation for this phenomenon may
involve the absorption of anti A/B antibodies by donor lymphocytes
thus eliminating at least part of the cellular repertoire responsible for the
induction and propagation of GVHD.29,32 Our findings also concur with
most prior publications in the field with regard to the incidence of dis-
ease relapse in the setting of ABO incompatibility. Indeed, data from
major cooperative groups in the field, namely the CIBMTR,33 the
National Marrow Donor Program28 and others,16,30,32 support our find-
ings essentially confirming that across multiple datasets and conditioning
regimens, ABO incompatibility has no bearing on the risk for relapse.
Lastly, as the stem cell source may in itself impact on clinical out-
come post-transplantation,34 we performed a separate analysis for a
smaller group of patients who received bone marrow derived grafts.
Again, similar to our earlier observations in the PB group, ABO status
did not affect outcome in MMURD transplanted patients. We note
that in general, studies examining ABO incompatibility both in bone
marrow derived grafts and in PB grafts indicated the lack of a prognos-
tic effect of ABO status.35 Interestingly, we also found that upon exclu-
sion of HLA-DQ mismatched patients, major ABO incompatibility
impacted favorably on the incidence of acute GVHD. The reasons for
this observation are not completely clear but are supported by data
previously published by Bacigalupo et al.29
We recognize the challenge of comparing the results of our
analysis, of a rather homogeneous AML cohort, to those of prior
studies, which consisted of a multitude of diseases comprising both
malignant and nonmalignant hematologic conditions. Additionally, as
with any retrospective multicenter analysis, there are recognized
inherent limitations affecting data collection and analysis. Impor-
tantly, we note that as our registry data was not annotated for clini-
cal data on transfusion requirements, clinically significant hemolysis,
and additional potentially prognosis modifying clinical factors we
cannot fully exclude a potential role for ABO incompatibility in influ-
encing outcome in MMURD.
In aggregate, our findings support the prevailing clinical notion that
ABO incompatibility has no major impact on patient prognosis probably
extends also to the population of adult AML patients undergoing
MMURD allogeneic stem cell transplantation.
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